Approximately 35% of Nuventra’s ongoing projects are for oncology indications. Our in-depth design and analysis of PK/PD studies can significantly enhance rational development of novel anticancer therapies. With our background in clinical pharmacology, we enable our clients to make better strategic decisions and improve their clinical and nonclinical studies. Nuventra’s consultants in pharmaceutical development consulting have more than 500 years of combined experience. Our specialized focus helps our clients avoid costly missteps and decrease the possibility of regulatory rejection.